Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Vascular pharmacology"
DOI: 10.1016/j.vph.2021.106858
Abstract: INTRODUCTION The ideal duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) is still unknown. In this meta-analysis, we aimed to compare very short-term (1-3 months), short-term (6 months), standard-term (12 months) and long-term (>12 months) DAPT… read more here.
Keywords: following percutaneous; risk; term; term dapt ... See more keywords
Comparison of Short- and Long-Term Dual-Antiplatelet Therapy After Transcatheter Aortic Valve Replacement: One-Year Outcomes
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Korean Medical Science"
DOI: 10.3346/jkms.2024.39.e294
Abstract: Background The optimal duration and net clinical benefit of dual antiplatelet therapy (DAPT) after transcatheter aortic valve replacement (TAVR) have not been elucidated in real-world situations. Methods Using nationwide claims data from 2013 to 2021,… read more here.
Keywords: term; long term; term dapt; short long ... See more keywords
Review: Long-term dual-antiplatelet therapy (DAPT) after PCI is no better than short-term DAPT, even with diabetes
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Internal Medicine"
DOI: 10.7326/acpjc-2017-166-4-022
Abstract: Questions What are the relative efficacy and safety of long-term and short-term dual antiplatelet therapy (DAPT) after implantation of drug-eluting stents (DESs)? Do outcomes differ in patients with or without diabetes? Review scope Included studies… read more here.
Keywords: term; term dapt; long term; mortality ... See more keywords